In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
|Videos|December 6, 2016
What Are the Challenges in Managing Pediatric Epilepsy?
Joseph Sullivan, MD—associate professor at the University of California San Francisco, director of USCF Pediatric Epilepsy Center—discusses some of the challenges in managing pediatric epilepsy.
Advertisement
Joseph Sullivan, MD—associate professor at the University of California San Francisco, director of USCF Pediatric Epilepsy Center—discusses some of the challenges in managing pediatric epilepsy.
Advertisement
Related to this article
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Why Patients Fear Statins Will Affect Their Memory
3
Suzetrigine After Knee Replacement: Are Fewer Opioid Prescriptions Enough?
4
Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4
5